Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics (NASDAQ:NLSP) and Aexon Labs expanded the DOXA platform with the AEX-6xx small-molecule series targeting arousal stability, cognition, and neuroprotection. Lead compound AEX-635 also modulates MRP1, which may aid neuroprotection and CNS bioavailability. The companies reported robust preclinical efficacy (up to 80% cataplexy reduction; >70% wakefulness increase) and plan IND-enabling studies. Financing includes ~$7M equity raised and a $25M equity line of credit, supporting operations for at least 12 months. Patents WO2024141660 and WO2024115797 are in national phases. NewCelX formation follows merger completion.
NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem announced that, following their merger completed as of Oct 29, 2025, the combined company NewCelX will continue development of the ITOL-102 Type 1 Diabetes cell therapy program with ongoing support from the BIRD Foundation.
The ITOL-102 program remains partnered with iTolerance and aims to develop a stem-cell-derived pancreatic islet therapy that avoids lifelong immunosuppression. The BIRD Foundation — which has invested >$300M in >1,000 joint projects generating >$10B in sales since 1977 — confirmed continued support under NewCelX's development framework.
NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) announced a 1-for-10 reverse share split effective in Switzerland on October 30, 2025, with Nasdaq reflecting the split at market open on October 31, 2025. Following the anticipated merger with Kadimastem, the company will change its name and trade under the new symbol NCEL. The new post‑merger CUSIP is H5835A109.
The amended capital structure lists total share capital of CHF 282,908.80, a capital band allowing issuance up to 2,859,412 common shares, conditional capital provisions, and specific outstanding share counts and warrant figures after the transactions.
NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) and Kadimastem (TASE: KDST) announced that all material conditions precedent for their merger have been satisfied or waived, and the merger closing is set for October 30, 2025. Nasdaq approved listing of the combined company's common shares.
The combined company will be named NewCelX Ltd. and listed on the Nasdaq Capital Market under the ticker NCEL beginning October 31, 2025. Kadimastem trading on TASE will be suspended and its final delisting is scheduled for October 31, 2025.
The final exchange ratio is 7.06 NLS common shares per Kadimastem share, which after a 1-for-10 reverse split of NLS shares becomes 0.706 NLS common shares per Kadimastem share. NewCelX shares are expected to be deposited to Kadimastem shareholders' accounts by the end of day November 3, 2025, with trading availability expected November 4, 2025 or soon thereafter.
NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem announced an MOU between Kadimastem and TargetGene to jointly develop next-generation gene-edited cell therapies, combining Kadimastem's AstroRx and IsletRx platforms with TargetGene's DNA-guided gene-editing technology.
The collaboration will operate under the combined company NewCelX upon completion of the anticipated merger between NLS and Kadimastem. The MOU frames joint R&D, technology exchange, and potential future licensing to enhance therapeutic performance, stability, and safety with a goal of scalable, curative cell-based treatments.
NLS Pharmaceutics (Nasdaq: NLSP / NLSPW) and Kadimastem (TASE: KDST) received Nasdaq approval for the combined company to list as NewCelX (NCEL) following the closing of their merger, expected on October 30, 2025, with trading under the new name to begin October 31, 2025, subject to customary closing conditions.
The approved exchange ratio yields Kadimastem shareholders ~84.4% ownership and NLS shareholders ~15.6% of the combined company; post-reverse split, each Kadimastem share equals ~0.62 NLS shares. Kadimastem ordinary shares are expected to be delisted from TASE around the closing. Warrant trading will not continue post-merger.
NewCelX will continue clinical programs: AstroRx Phase 2a for ALS and IsletRx pre-IND work toward a Phase 1 diabetes trial; technology transfer and GMP manufacturing setup with Pluri completed.
NLS Pharmaceutics (NASDAQ: NLSP) shareholders have approved the merger with Kadimastem (TASE: KDST) at an Extraordinary General Meeting on September 29, 2025. The combined company will be renamed NewCelX Ltd. and trade on Nasdaq under the ticker "NCEL".
Under the approved terms, Kadimastem shareholders will own 84.4% of the combined company, while NLS shareholders will retain 15.6%. The merger unites Kadimastem's cell therapy programs, including a Phase 2a ALS study of AstroRx® and IsletRx diabetes program, with NLS's CNS small-molecule expertise. Ronen Twito will serve as Executive Chairman & CEO, while Prof. Michel Revel, Kadimastem's founder and developer of the successful MS drug Rebif®, will become Chief Scientific Officer.
NLS Pharmaceutics (NASDAQ:NLSP) and Kadimastem (TASE:KDST) announced the SEC's approval of their Form F-4 registration statement for their planned merger. The combined entity will be named NewCelX Ltd. and trade on Nasdaq as "NCEL".
The merger will unite Kadimastem's cell therapy platforms with NLS's small-molecule expertise. Key programs include Kadimastem's AstroRx®, preparing for Phase 2a trials in ALS, and IsletRx, a stem cell-derived therapy for insulin-dependent diabetes developed with iTolerance. The extraordinary general meeting is scheduled for September 29, 2025.
NLS Pharmaceutics (NASDAQ:NLSP) and its merger partner Kadimastem have secured a significant patent in Hong Kong for their cell selection and enrichment technology used in developing IsletRx, a stem cell-derived therapy targeting insulin-dependent diabetes. The patent complements existing protections in Europe, the United States, and India.
The technology enables the selection of highly functional islet cells from differentiated cell populations to maximize therapeutic effect. Hong Kong represents a strategic market with approximately 706,000 adults living with diabetes (8.2% prevalence) and an estimated economic impact of $90 billion, based on average lifetime healthcare expenditures of $125,000 per patient.
NLS Pharmaceutics (NASDAQ:NLSP) announced that the BIRD Foundation has approved an additional milestone payment of $166,000 to Kadimastem and iTolerance for their iTOL-102 diabetes program. This brings total BIRD Foundation support to $882,352.
The milestone follows a successful Pre-IND meeting with the FDA regarding iTOL-102, a potential cure for Type 1 diabetes that combines Kadimastem's IsletRx technology with iTolerance's iTOL-100 immunomodulatory platform. The therapy aims to eliminate the need for life-long immunosuppression drugs.
Preclinical studies at the University of Miami's Diabetes Research Institute have shown promising results, demonstrating functional insulin secretion and disease reversal in diabetic animal models. The companies are now preparing for safety toxicology studies and clinical trial submissions.
FAQ
What is the current stock price of Nls Pharmaceutics (NLSP)?
What is the market cap of Nls Pharmaceutics (NLSP)?
